Michelle Sidor

Company: Alchemab Therapeutics Ltd

Job title: Director of Neuroscience

Seminars:

Mining Patient Resiliency-Associated Targets for Novel Antibody Therapeutics: Discovery of the CD33 antibody, ATLX-1088 11:30 am

Sequencing the B cell repertoire from resilient patient populations to look for protective auto-antibodies in an unbiased manner Identifying resilient autoantibodies to uncover novel targets and pathways for target discovery Harnessing the neuroprotective activity of microglia within the 1088 program as a novel antibody therapeuticRead more

day: Discovery Track AM